NAUTILUS BIOTECHNOLOGY INC's ticker is NAUT and the CUSIP is 63909J108. A total of 75 filers reported holding NAUTILUS BIOTECHNOLOGY INC in Q1 2023. The put-call ratio across all filers is 443.25 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $103,304 | -18.3% | 32,691 | 0.0% | 0.00% | – |
| Q2 2023 | $126,514 | +10.3% | 32,691 | -21.0% | 0.00% | – |
| Q1 2023 | $114,670 | +223.8% | 41,397 | +110.4% | 0.00% | – |
| Q4 2022 | $35,417 | -13.6% | 19,676 | +1.6% | 0.00% | – |
| Q3 2022 | $41,000 | -32.8% | 19,358 | -14.1% | 0.00% | – |
| Q2 2022 | $61,000 | – | 22,536 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| AH Equity Partners Bio II, L.L.C. | 16,298,006 | $70,733,000 | 40.75% |
| Madrona Venture Group, LLC | 6,020,770 | $26,130,000 | 7.74% |
| AH Equity Partners LSV II, L.L.C. | 1,355,911 | $5,885,000 | 4.24% |
| Ally Bridge Group (NY) LLC | 1,080,566 | $4,690,000 | 3.48% |
| ArchPoint Investors | 1,449,551 | $6,291,000 | 2.17% |
| Tikvah Management LLC | 1,488,895 | $6,462,000 | 2.07% |
| Bain Capital Life Sciences Investors, LLC | 2,000,000 | $8,680,000 | 0.84% |
| Perceptive Advisors | 9,111,151 | $39,542,000 | 0.79% |
| SPHERA FUNDS MANAGEMENT LTD. | 840,000 | $3,646,000 | 0.52% |
| Decheng Capital Management III (Cayman), LLC | 300,000 | $1,302,000 | 0.40% |